Scotland’s decision to approve donanemab for use on the NHS is a landmark moment for Alzheimer’s treatment. It shows that progress is happening — and that new treatments can reach people who need them.
But this breakthrough also exposes a growing divide. People in England, Wales and Northern Ireland are still unable to access donanemab through the NHS, creating a postcode lottery for care.
Access to life-changing treatment should not depend on where someone lives. That’s why we’re calling on the Department of Health and Social Care to show national leadership and work towards fair, UK-wide access to donanemab — so no one is left behind.